Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/eci.13383

http://scihub22266oqcxt.onion/10.1111/eci.13383
suck pdf from google scholar
32810285!7460924!32810285
unlimited free pdf from europmc32810285    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32810285      Eur+J+Clin+Invest 2020 ; 50 (11): e13383
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis #MMPMID32810285
  • Misra S; Nath M; Hadda V; Vibha D
  • Eur J Clin Invest 2020[Nov]; 50 (11): e13383 PMID32810285show ga
  • BACKGROUND: Several therapeutic agents have been investigated for treatment of novel coronavirus 2019 (nCOV-2019). We conducted a systematic review and meta-analysis to assess the efficacy of various treatment modalities in nCOV-2019 patients. METHODS: A literature search was conducted before 29 June 2020 in PubMed, Google Scholar and Cochrane library databases. A fixed-effect model was applied if I(2) < 50%, else results were combined using random-effect model. Risk ratio (RR) or standardized mean difference (SMD) along with 95% confidence interval (95% CI) was used to pool the results. Between-study heterogeneity was explored using influence and sensitivity analyses, and publication bias was assessed using funnel plots. Entire statistical analysis was conducted in R version 3.6.2. RESULTS: Fifty studies involving 15 in vitro and 35 clinical studies including 9170 nCOV-2019 patients were included. Lopinavir-ritonavir was significantly associated with shorter mean time to clinical recovery (SMD -0.32; 95% CI -0.57 to -0.06), remdesivir was significantly associated with better overall clinical recovery (RR 1.17; 95% CI 1.07 to 1.29), and tocilizumab was associated with less all-cause mortality (RR 0.38; 95% CI 0.16 to 0.93). Hydroxychloroquine was associated with longer time to clinical recovery and less overall clinical recovery. It additionally had higher all-cause mortality and more total adverse events. CONCLUSION: Our meta-analysis suggests that except in vitro studies, no treatment has shown overall favourable outcomes in nCOV-2019 patients. Lopinavir-ritonavir, remdesivir and tocilizumab may have some benefits, while hydroxychloroquine administration may cause harm in nCOV-2019 patients. Results from upcoming large clinical trials may further clarify role of these drugs.
  • |Adenosine Monophosphate/administration & dosage/analogs & derivatives[MESH]
  • |Alanine/administration & dosage/analogs & derivatives[MESH]
  • |Antibodies, Monoclonal, Humanized/administration & dosage[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Coronavirus Infections/diagnosis/*drug therapy/*epidemiology[MESH]
  • |Europe[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Lopinavir/administration & dosage[MESH]
  • |Male[MESH]
  • |Pandemics/prevention & control/statistics & numerical data[MESH]
  • |Pneumonia, Viral/diagnosis/*drug therapy/*epidemiology[MESH]
  • |Prognosis[MESH]
  • |Ritonavir/administration & dosage[MESH]
  • |Survival Analysis[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box